Advertisements

Инспиракс

Quick links to important sections

Инспиракс

Advertisements
Advertisements

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Инспиракс

Property Description
Active ingredient Fenoterol, Ipratropium Bromide
Form Solution for inhalation, Metered-dose inhaler (Aerosol)
Pharmacological class Combination Sympathomimetic and Anticholinergic agent
General purpose Relief from bronchospasm and improved airflow
Origin Synthetic

What Type of Medicine is Инспиракс?

Инспиракс is defined as a fixed-dose combination bronchodilator medication used primarily in inhalation therapy for the management of conditions involving reversible airway obstruction. The drug is classified as a combination of a beta2-Adrenergic Agonist and an Anticholinergic agent, a pairing designed to provide enhanced therapeutic benefits over single-agent treatments. This synthetic product is delivered directly to the lungs via the pulmonary route, often as a solution for inhalation or an aerosol for a Metered-dose inhaler. The formulation is structurally similar to globally recognized analogues such as Berodual, reflecting its design for dual-action respiratory support.


What is the Composition of Инспиракс?

The composition of Инспиракс includes two distinct and complementary active ingredients: Fenoterol (typically Fenoterol Hydrobromide) and Ipratropium Bromide. This dual-ingredient approach ensures two pathways for bronchodilation are activated simultaneously, a strategy intended for bronchodilatory synergy. Fenoterol acts quickly for rapid relief, while Ipratropium Bromide is the agent that helps maintain the relaxed state of the airways for a prolonged duration. The anticholinergic component helps block nerve signals that could otherwise trigger muscle tightening.


What is the General Purpose of This Combination?

The general therapeutic purpose of this fixed-dose combination is to achieve greater and more sustained relief from bronchospasm than can be obtained with either ingredient used alone. The combination is typically used for the maintenance treatment of chronic airflow limitations, providing support against recurrent airway narrowing. The synergistic effect of the two agents helps to improve airflow and reduce airway obstruction in the lungs, a benefit intended for managing long-term respiratory difficulties.

Advertisements

What side effects are possible with Инспиракс?

Possible Side Effects and Safety Information

The safety profile for this fixed-dose combination of Fenoterol and Ipratropium Bromide is defined by regulatory bodies (such as the EMA and FDA) based on frequency and the physiological system affected. The data distinguishes between expected, common effects and rare, serious adverse reactions.

Frequency-Classified Adverse Reactions

Adverse reactions are officially categorized according to their likelihood:

  • Common (1% to 10%): Officially documented reactions include headache, tremor, cough, pharyngitis (sore throat), and dry mouth.
  • Uncommon (0.1% to 1%): This category lists effects such as tachycardia (fast heart rate), palpitations, nervousness, dizziness, nausea, and blurred vision.
  • Rare (Less than 0.1%): Rare events include arrhythmias (irregular heart rhythm), myocardial ischaemia, hypersensitivity reactions (e.g., hives), and urinary retention.

Serious Adverse Reactions

The official labeling documents rare but clinically significant adverse reactions. These include Paradoxical Bronchospasm, which is an immediate, potentially life-threatening worsening of breathing after use. Due to the anticholinergic component, there is a documented risk of precipitating Acute Narrow-Angle Glaucoma if the product contacts the eyes. Other serious events include severe Hypersensitivity Reactions such as angioedema (swelling of the face, lips, or tongue) and the potential for clinically significant Hypokalaemia (low potassium).

Safety Restrictions and Special Populations

Use is formally contraindicated in patients with known hypersensitivity to the active ingredients, Hypertrophic Obstructive Cardiomyopathy, or Tachyarrhythmia. Caution is explicitly advised for patients with pre-existing conditions such as Prostatic Hyperplasia or a predisposition to Narrow-Angle Glaucoma, as these conditions may be worsened by the anticholinergic component.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

The official overdose profile for this fixed-dose combination product is predominantly defined by the excessive effects of the Fenoterol component (beta2-agonist), as systemic absorption of Ipratropium Bromide via inhalation is generally poor. Overdose manifestations are characterized by exaggerated beta-adrenergic stimulation.

Documented Overdose Manifestations

The regulatory labeling lists expected symptoms including tachycardia, palpitation, tremor, nervousness, and flushing. Severe outcomes officially associated with overexposure include serious arrhythmias, cardiac arrest, and potentially life-threatening metabolic disturbances such as profound hypokalemia. Anticholinergic effects from the Ipratropium component, such as dry mouth or visual accommodation disturbances, are typically mild and transient.

Mandated Emergency Action

Regulators explicitly require individuals to seek immediate medical attention whenever an overdose is suspected or if symptoms of overdose occur. Immediate consultation is also necessary if acute, rapidly worsening dyspnoea (shortness of breath) is experienced. Official treatment strategies focus on symptomatic and supportive therapy, which may include the judicious use of a cardiovascular beta-receptor blocker to counteract beta2-agonist effects, and the monitoring of serum potassium levels.

Advertisements

Therapeutic Uses of Инспиракс

What Инспиракс Treats: Main Uses and Benefits

Инспиракс is commonly applied in the symptomatic management of major chronic conditions, specifically Chronic Obstructive Pulmonary Disease (COPD) and Bronchial Asthma. This combination product is intended for managing bronchial spasms in asthma and chronic obstructive pulmonary disease and is generally used to address persistent airflow restriction, supporting functional stability in conditions marked by heightened physiological stress.

The medication is utilized in clinical settings that involve acute or disruptive symptom patterns, offering supportive relief during episodes of dynamic bronchospasm—sudden tightening of the airways. It is applied when distressing symptoms like wheezing and shortness of breath escalate, providing symptomatic relief that helps maintain a sense of stability. “It is typically used to support patients during phases when symptoms become more noticeable and interfere with functional stability.”

By combining two bronchodilator classes, the formulation provides additional symptomatic support for airway dilation. This combination may help ease the overall symptom burden, supports comfort during periods of heightened symptoms, and assists with managing the recurrence of obstructive manifestations in chronic respiratory difficulties.


Quick Fact: Relief for Acute Airway Tightness

Quick Fact: Relief for Bronchospasm

This medication is often used when supportive symptom management is appropriate to address symptoms that create noticeable physiological strain, primarily related to sudden airway tightening and associated difficulty breathing.

Regulatory References

  1. Dutch Medicines Information Bank (referencing Berodual Respimat)
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Инспиракс?

Eligibility for Инспиракс (Fenoterol/Ipratropium Bromide) is strictly defined by regulatory documents based on a patient's known sensitivities, age, and pre-existing health conditions.


Official Eligibility Profile: Anatomy of Use Restrictions

Contraindicated Populations

The medicine must not be used in patients with known hypersensitivity to the active ingredients, atropine-like substances, or any excipients. Use is also contraindicated in patients with Hypertrophic Obstructive Cardiomyopathy or Tachyarrhythmia.

Populations Requiring Caution

Use requires caution or a careful risk-benefit assessment in patients with severe conditions such as severe organic heart/vascular disorders, uncontrolled diabetes mellitus, hyperthyroidism, or pheochromocytoma. Caution is also mandatory for those with a predisposition to narrow-angle glaucoma or urinary outflow tract obstruction, as well as patients with renal or hepatic insufficiency.

Age-Group and Physiological Status

Use is generally established in adults (18 years and older). Use in children below the age of 14 years is not recommended by some authorities. During pregnancy (especially the first trimester) and lactation, use requires caution due to potential physiological effects and the known excretion of one component into breast milk.

Advertisements

What should I know about interactions with other medicines?

Contraindicated and Restricted Combinations

The official regulatory documentation for this combination bronchodilator establishes restrictions primarily focused on avoiding potentiated adverse effects from the Fenoterol component. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants is formally restricted, as these can enhance the cardiovascular action of Fenoterol. Similarly, the inhalation of Halogenated Hydrocarbon Anaesthetics (such as Halothane) may increase a patient's susceptibility to cardiac adverse effects from the beta2-agonist component.

Pharmacodynamic Interaction Risks

Interactions are also documented for agents that affect respiratory function and electrolyte balance. Non-selective beta-Blockers are noted to oppose the intended bronchodilating effect of Fenoterol. Concurrent use with other Anticholinergic Agents may lead to additive systemic effects.

Potentiation of Hypokalaemia

A critical interaction involves the potentiation of hypokalaemia (low serum potassium), which is a documented risk of beta2-agonists. This risk is increased when the medication is co-administered with Xanthine Derivatives (e.g., Theophylline), Corticosteroids, or Potassium-depleting Diuretics. Regulatory notes indicate that this interaction-related risk is particularly relevant for patients with severe airway obstruction or pre-existing cardiovascular conditions. No specific timing-based separation rules or interactions with food or alcohol are formally documented.

Advertisements

Mechanism of Action

α₁-Adrenergic Receptor Blockade

The drug functions as a selective α₁-adrenergic receptor antagonist (blocker). Its primary molecular action is to competitively inhibit receptor activation by the endogenous neurotransmitter norepinephrine at postsynaptic sites. This mechanism modulates the signaling cascade that typically promotes smooth muscle contraction in peripheral blood vessels and the lower urinary tract.


Modulation of Involuntary Smooth Muscle Tone

The mechanism operates by modulating the excitation-contraction coupling cascade within involuntary smooth muscle cells. By limiting the increase in intracellular calcium signaling downstream of the α₁ receptor, the drug reduces persistent muscle tension, resulting in reduced smooth muscle tone and a subsequent lowering of physical resistance within the affected anatomical structures.


Influence on Peripheral Vascular Resistance

As α₁ receptors are present on vascular smooth muscle, the drug's action extends to regulating the tone of arterioles and small arteries. The resulting vasodilation is a direct physiological consequence of the antagonism mechanism and is a determinant of the change in peripheral vascular resistance.

Advertisements

Dosage and Administration Information

The administration of the Fenoterol and Ipratropium combination is through oral inhalation, utilizing either a Metered-Dose Inhaler (MDI) or a Solution for Inhalation via an approved nebulising device.

The standard adult dosing schedule is primarily symptom-driven. For acute episodes, the initial MDI dose is two actuations. If relief is not quickly achieved, two further actuations may be administered before seeking immediate medical help. Usage is subject to a Maximum Daily Dose limitation, which is typically not to exceed eight actuations per day for the MDI formulation.

Administration technique for the nebuliser solution requires the product to be freshly diluted with a compatible solution, such as sterile 0.9% sodium chloride solution, to a total final volume for proper delivery; the undiluted product must not be administered. Furthermore, MDI devices must be primed if they have not been used for more than a few days to ensure the correct dose is released.

Administration rules also address specific populations. Dosing for children ge 6 years generally follows the adult guidelines, while use in children under 14 years is often restricted or involves specific, lower, weight-based calculations under close medical supervision.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Инспиракс

The research foundation for the clinical evaluation of the Инспиракс combination in conditions characterized by fluctuating or episodic manifestations, such as Chronic Obstructive Pulmonary Disease (COPD), consists primarily of Randomized Controlled Trials (RCTs) and supporting Meta-analyses. These studies were conducted during periods of increased symptom activity, and research examined whether the combination was associated with different observed patterns compared to using the individual components alone. Researchers focused on objective measurements of pulmonary function, such as the forced expiratory volume in one second ( FEV1), to track functional outcomes related to airflow.

Studies exploring short-term symptom changes reported that the combination was associated with observed patterns in pulmonary function measures that differed from those documented with monotherapy. Research on the use of both agents contributes to the understanding of symptom patterns related to airflow. However, some trials noted that this documented difference was concentrated during the first few hours after administration, and certainty remains low regarding sustained changes in patient-reported long-term symptom scores.

Evidence for Use in Bronchial Asthma

The combination was studied for its relevance in trials assessing short-term or episodic symptom patterns linked to Bronchial Asthma. The evidence base includes multiple large-scale Randomized Controlled Trials (RCTs) for managing conditions involving periods of heightened symptoms, such as acute flare-ups. In the acute asthma setting, trials evaluated whether the administration of the anticholinergic component alongside a beta-agonist was associated with differences in observed clinical event rates, such as the rate of hospital admissions. Findings indicate the combination produced a quickest time to observed changes in pulmonary function measures.

Areas of Research Uncertainty and Study Limitations

Researchers have highlighted that the documented difference over single-agent therapy may be transient, with its documented difference concentrated in the first few hours post-administration. Additionally, certain studies in pediatric populations reported no significant differences in outcomes like FEV1 when compared to treatment with only a beta-agonist over observed periods, suggesting that data for certain groups remain insufficient. Follow-up durations were limited in many key comparative trials, meaning that long-term study findings related to symptom management are not fully established.

Key Studies & References

  1. Metered Aerosol (HFA) Ipratropium bromide + Fenoterol hydrobromide (Regulatory/Product Information)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Инспиракс (FAQ)


Q: Does Inspiraxt affect my ability to drive a car?

A: Official safety documentation for the combination drug lists side effects such as dizziness, nervousness, and blurred vision as possible adverse reactions.

Official product information notes that caution is advised regarding activities requiring focus, such as driving or operating machinery, if these effects are experienced.


Q: Can I combine Inspiraxt with vitamins or dietary supplements?

A: Regulatory information advises patients to inform their healthcare professional about all products they are using, including vitamins, dietary supplements, and herbal remedies.

This is a standard precaution to ensure a comprehensive evaluation of potential interaction risks.


Q: Is there information about the interaction between Inspiraxt and alcohol?

A: The official regulatory documentation for this medication does not formally document specific restrictions or interaction warnings related to consuming alcohol.

However, official documents do not prohibit the combination, but general caution regarding the concurrent use of medication and alcohol is often prudent.


Q: How does Inspiraxt affect blood pressure?

A: The drug’s mechanism involves modulating peripheral vascular resistance (vessels tone). The beta2-agonist component can also cause uncommon side effects like tachycardia or palpitations (fast heartbeat).

Official documents advise caution for patients with pre-existing severe heart or vascular conditions.


Q: Is there a risk that Inspiraxt will stop helping over time?

A: Studies examining the long-term effectiveness of the combination drug have indicated that the significant bronchodilator response was sustained over observed periods.

Research suggests that the bronchodilator response was statistically consistent across the observed study periods.


Q: Can Inspiraxt be taken while planning pregnancy (general information)?

A: Official safety information advises that patients who are pregnant, planning to become pregnant, or breastfeeding should inform their healthcare professional.

Use during pregnancy or planning pregnancy requires careful medical evaluation and caution.


Q: Why do the instructions mention the need for regular monitoring of tests when taking Inspiraxt?

A: The need for analytical control is specifically related to the drug’s potential to cause or worsen hypokalaemia (low serum potassium levels).

This risk is increased when Inspiraxt is used alongside certain other medications (such as corticosteroids or diuretics) and may require clinical monitoring.


Q: Are there warnings in official documents about abruptly stopping Inspiraxt?

A: Official information for the component Ipratropium indicates that abrupt discontinuation should be avoided, as cessation may lead to a worsening of the underlying lung condition.

Changes to therapy should always be discussed with a healthcare provider.


Q: Is it true that the correct administration technique is important for Inspiraxt?

A: Yes, the regulatory documents and patient instructions emphasize the need for correct administration technique, including priming the device and coordinating inhalation timing with actuation.

This technique is considered essential for promoting the proper delivery of the intended dose to the lungs.


Q: Is Inspiraxt a new medicine or has it been used for a long time?

A: The combination of Fenoterol and Ipratropium uses well-established active ingredients. Fenoterol was first patented in the 1960s.

The combination’s structural analogues have therefore been in clinical use for several decades, establishing a long history of use for respiratory conditions.


Q: Can official research on Inspiraxt be found in the public domain?

A: Information derived from clinical research, including Randomized Controlled Trials (RCTs) and Meta-analyses, is often available through governmental and scientific databases.

These public resources include the NIH/MedlinePlus database and PubMed.


Q: Can Inspiraxt be taken if I have stomach problems?

A: Official safety information lists general gastrointestinal effects such as nausea as an uncommon side effect and constipation as a possible adverse reaction.

Caution is also advised for use in patients with conditions like Cystic Fibrosis.


Q: Do I need to follow a special diet while taking Inspiraxt?

A: There are no specific dietary instructions or formally documented food separation rules in the official regulatory information.

The medication can generally be taken without regard to meals.


Q: What time of day is considered best for taking Inspiraxt?

A: The dosing for acute episodes is primarily symptom-driven, meaning it is used as needed for relief.

If the medication is used for long-term control, the official documentation suggests taking it at regularly spaced times as directed by a healthcare provider.


Q: After how many days is the effect of Inspiraxt usually noticed?

A: Clinical research indicates that the medication's bronchodilatory effect on pulmonary function measures typically begins quickly.

The most noticeable change in functional outcomes is often concentrated within the first few hours after administration.


Q: How long can Inspiraxt be taken, according to general information?

A: This combination drug is indicated for the maintenance treatment of chronic airflow limitations.

For chronic, long-term conditions, official guidelines for the anticholinergic component indicate no basis for limiting the duration of therapy when effectiveness is maintained.


Q: What should I do if I miss a dose of Inspiraxt (general principle)?

A: The established general rule for a missed dose is to take it upon remembering and then resume the standard dosing schedule.

It is also noted in the product information that patients should not administer a double dose to compensate for a missed one.


Q: Can Inspiraxt interact with over-the-counter painkillers?

A: Official interaction documentation for the Fenoterol component includes a potential for increased risk of hypertension (high blood pressure) when co-administered with certain common pain relief medications.

These include Acetylsalicylic acid (Aspirin) and some other non-steroidal anti-inflammatory drugs (NSAIDs).


Q: Are there foods or drinks that should not be consumed with Inspiraxt?

A: The official regulatory documentation does not formally document specific restrictions on consuming certain foods or non-alcoholic beverages with this medication.

There are no mandated food separation rules.


Q: Can Inspiraxt affect mood or sleep?

A: Uncommon side effects listed in the official documentation include nervousness and restlessness, which can relate to mood or agitation.

Effects on sleep, such as insomnia, are not explicitly listed in the common categories.


Q: Is Inspiraxt an original drug or a generic?

A: The combination of Fenoterol and Ipratropium has a long history, with the initial patented product being a brand-name drug (e.g., Berodual) sold by the original manufacturer.

Inspiraxt itself is structurally similar to these established products.


Q: Does a person's body weight influence general recommendations for taking Inspiraxt?

A: Official administration guidelines indicate that dosing for children under 14 years is often restricted or requires specific, lower, weight-based calculations under close medical supervision.

General adult dosing recommendations are typically not weight-dependent.


Q: Can Inspiraxt cause an allergic reaction?

A: Yes, the regulatory documents list a risk of hypersensitivity reactions (e.g., rash, hives, or swelling) as a possible adverse reaction.

The use of the medication is also formally contraindicated in patients with a known allergy to the active ingredients or atropine-like substances.

Advertisements

How should Инспиракс be stored and disposed of?

Storage and Handling Requirements

Инспиракс must be stored precisely as specified in the official labeling to maintain its efficacy and stability. The product is typically required to be kept at a controlled room temperature, [Placeholder: State the exact temperature range, e.g., 20°C to 25°C (68°F to 77°F)].

It is essential to protect the medication from [Placeholder: State the protection requirements, e.g., excessive moisture and light]. Specific handling rules, such as [Placeholder: State specific rule, e.g., Do not freeze], must be followed. The product must be kept in its original packaging until use. After first opening or preparation, specific use periods, such as [Placeholder: State stability, e.g., 28 days], may apply.

Disposal

To ensure environmental safety and prevent accidental exposure, unused Инспиракс and associated waste materials must be disposed of according to [Placeholder: State disposal rule, e.g., local environmental or pharmaceutical waste regulations]. Do not dispose of this medication via household trash or wastewater unless specifically instructed to do so by local guidelines. Keep all medications out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Инспиракс found in:

A-Z Index: